Citations

Clear

2429 citation(s) found for "Shah, SS".

Deep Brain Stimulation: Technology at the Cutting Edge
Shah, Rahul S. , Chang, Su-Youne , Min, Hoon‐Ki , Cho, Zang‐Hee , Blaha, Charles D. , Lee, Kendall H. , Min, Hoon-Ki Paul , Blaha, Charles

Mayo Clinic

Journal of Clinical Neurology | January 20, 2011 | Volume: 6 | Issue: 4 | Pages: 167

10.3988/jcn.2010.6.4.167 | PMID 21264197 Get It

Primary CNS Lymphoma in Children and Adolescents: A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)
Abla, Oussama , Weitzman, Sheila, Blay, Jean‐Yves , Abrey, Lauren E. , Neuwelt, Edward A. , Doolittle, Nancy D., Baehring, Joachim M. , Pradhan, Kamnesh R. , Martin, Sheelagh, Guerrera, Michael F., Shah, Shafqat, Ghesquières, Hervé , Silver, Michael, Batchelor, Tracy T. , O’Neill, Brian Patrick , Betensky, Rebecca A. , Blay, Jean-Yves

Mayo Clinic

Clinical Cancer Research | January 12, 2011 | Volume: 17 | Issue: 2 | Pages: 346-352

10.1158/1078-0432.ccr-10-1161 | PMID 21224370 Get It

Abstract Purpose: To describe the demographic and clinical features and outcomes for children and adolescents with primary CNS lymphoma (PCNSL). Experimental Design: A retrospective series of children and adolescents with PCNSL was assembled from 10 cancer centers in 3 countries. Results: Twenty-nine patients with a median age of 14 years were identified. Sixteen (55%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or greater. Frontline therapy consisted of chemotherapy only in 20 patients (69%), while 9 (31%) had chemotherapy plus cranial radiotherapy. Most patients received methotrexate (MTX)-based regimens. Overall response rate was 86% (complete remission 69%, partial remission 17%). The 2-year progression-free survival (PFS) and overall survival (OS) rates were 61% and 86%, respectively; the 3-year OS was 82%. Univariate analyses were conducted for age (≤14 vs. >14 years), PS (0 or 1 vs. >1), deep brain lesions, MTX dose, primary treatment with chemotherapy alone, intrathecal chemotherapy, and high-dose therapy. Primary treatment with chemotherapy alone was associated with better overall response rates with an odds ratio (OR) of 0.125 (P = 0.02). There was a marginally significant relationship between higher doses of MTX and response (OR = 1.5, P = 0.06). ECOG-PS of 0 to 1 was the only factor associated with better outcome with hazard ratios of 0.136 (P = 0.017) and 0.073 (P = 0.033) for PFS and OS, respectively. Conclusion: This is the largest series collected of pediatric PCNSL. The outcome of children and adolescents seems to be better than in adults. PS of 0 to 1 is associated with better survival. Clin Cancer Res; 17(2); 346–52. ©2011 AACR.
Predicting which medication classes interfere with allergy skin testing
Shah, Kunal , Rank, Matthew A. , Davé, Shoban A., Oslie, C.L., Butterfield, Joseph H.

Mayo Clinic

Allergy and Asthma Proceedings | December 13, 2010 | Volume: 31 | Issue: 6 | Pages: 477-482

10.2500/aap.2010.31.3382 | PMID 21708059 Get It

Lifetime Costs of Medical Care After Heart Failure Diagnosis
Shah, Nilay D. , Shi, Qian , Morlan, Bruce W., VanHouten, Holly, Long, Kirsten Hall , Roger, Véronique L. , Dunlay, Shannon M. , Shi, Qian

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | December 8, 2010 | Volume: 4 | Issue: 1 | Pages: 68-75

10.1161/circoutcomes.110.957225 | PMID 21139091 Get It

Background— Heart failure (HF) care constitutes an increasing economic burden on the health care system, and has become a key focus in the health care debate. However, there are limited data on the lifetime health care costs for individuals with HF after initial diagnosis. Methods and Results— Olmsted County residents with incident HF from 1987 to 2006 were identified. Direct medical costs incurred from the time of HF diagnosis until death or last follow-up were obtained using population-based administrative data through 2007. Costs were inflated to 2008 US dollars using the general Consumer Price Index. Inpatient, outpatient, and total costs were estimated using a 2-part model with adjustment for right censoring of data. Predictors of total costs were examined using a similar model. A total of 1054 incident HF patients were identified (mean age, 76.8 years; 46.1% men). After a mean follow-up of 4.6 years, 765 (72.6%) patients had died. The estimated total lifetime costs were $109 541 (95% confidence interval, $100 335 to 118 946) per person, with the majority accumulated during hospitalizations (mean, $83 980 per person). After adjustment for age, year of diagnosis, and comorbidity, diabetes mellitus and preserved ejection fraction (≥50%) were associated with 24.8% ( P =0.003) and 23.6% ( P =0.041) higher lifetime costs, respectively. Higher costs were observed at initial HF diagnosis and in the months immediately before death in those surviving >12 months after diagnosis. Conclusions— HF imposes a significant economic burden, primarily related to hospitalizations. Variations in cost over a lifetime can help identify strategies for efficient management of patients, particularly at the end of life.
Testing for HER2 in Breast Cancer: A Continuing Evolution
Shah, Sejal , Chen, Beiyun

Mayo Clinic

Pathology Research International | December 6, 2010 | Volume: 2011 | Issue: No issue available | Pages: 1-16

10.4061/2011/903202 | PMID 21188214 Get It

Human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive factor in breast cancer. HER2 is overexpressed in approximately 15%–20% of invasive breast carcinomas and is associated with earlier recurrence, shortened disease free survival, and poor prognosis. Trastuzumab (Herceptin) a “humanized” monoclonal antibody targets the extracellular domain of HER2 and is widely used in the management of HER2 positive breast cancers. Accurate assessment of HER2 is thus critical in the management of breast cancer. The aim of this paper is to present a comprehensive review of HER2 with reference to its discovery and biology, clinical significance, prognostic value, targeted therapy, current and new testing modalities, and the interpretation guidelines and pitfalls.
Variation in Prevalence, Diagnostic Criteria, and Initial Management Options for Eosinophilic Gastrointestinal Diseases in the United States
Spergel, Jonathan M. , Book, Wendy , Mays, Elizabeth, Song, L, Shah, Samir S. , Bonis, Peter A, Talley, Nicholas J.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | November 6, 2010 | Volume: 52 | Issue: 3 | Pages: 300-306

10.1097/mpg.0b013e3181eb5a9f | PMID 21057327 Get It

ABSTRACTObjectives:Variation in the prevalence of eosinophilic gastrointestinal diseases in different geographical regions has not been extensively studied. The aim of the present study was to define the regional and national prevalence of eosinophilic gastrointestinal diseases, and differences in practice approaches.Patients and Methods:We administered a survey electronically to members of the American College of Gastroenterology, the American Academy of Allergy, Asthma, and Immunology, and the North American Society Pediatric Gastroenterology, Hepatology, and Nutrition. Questions pertained to the number and proportion of patients seen with eosinophilic gastroenteritis or colitis and eosinophilic esophagitis (EoE), and methods used to diagnose and treat these conditions.Results:A total of 1836 physicians responded from 10,874 requests (17% response). Extrapolating responses from our US sample, we estimated an overall prevalence of 52 and 28/100,000 for EoE and eosinophilic gastroenteritis or colitis. The patient burden of EoE is higher in urban (0.58) and suburban (0.44) compared with rural settings (0.36, P < 0.0065), observations consistent with other allergic disorders. There was also increased prevalence in northeast region when calculated by prevalence per 100,000. There was considerable variability in criteria and initial treatment options used to diagnose EoE. Only one‐third of respondents reported using diagnostic criteria proposed in a 2007 consensus document. Seventy‐one and 35% of respondents reported treating some patients with EoE with a food elimination or elemental diet, respectively.Conclusions:EoE is diagnosed more often in northeastern states and urban areas. There is considerable variability in diagnostic criteria and initial treatment approach supporting the need for additional clinical trials and consensus development.
Direct Medical Costs of Constipation From Childhood to Early Adulthood: A Population‐based Birth Cohort Study
Choung, Rok Seon , Shah, Nilay D. , Chitkara, Denesh K., Tilburg, Miranda A.L. van , Whitehead, William E. , Katusic, Slavica K., Locke, G. Richard, Talley, Nicholas J. , Branda, Megan E. , Choung, Rok Seon

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | September 30, 2010 | Volume: 52 | Issue: 1 | Pages: 47-54

10.1097/mpg.0b013e3181e67058 | PMID 20890220 Get It

ABSTRACTBackground:Although direct medical costs for constipation‐related medical visits are thought to be high, to date there have been no studies examining whether longitudinal resource use is persistently elevated in children with constipation. Our aim was to estimate the incremental direct medical costs and types of health care use associated with constipation from childhood to early adulthood.Methods:A nested case‐control study was conducted to evaluate the incremental costs associated with constipation. The original sample consisted of 5718 children in a population‐based birth cohort who were born during 1976 to 1982 in Rochester, MN. The cases included individuals who presented to medical facilities with constipation. The controls were matched and randomly selected among all noncases in the sample. Direct medical costs for cases and controls were collected from the time subjects were between 5 and 18 years of age or until the subject emigrated from the community.Results:We identified 250 cases with a diagnosis of constipation in the birth cohort. Although the mean inpatient costs for cases were $9994 (95% Confidence interval [CI] 2538–37,201) compared with $2391 (95% CI 923–7452) for controls (P = 0.22) during the time period, the mean outpatient costs for cases were $13,927 (95% CI 11,325–16,525) compared with $3448 (95% CI 3771–4621) for controls (P < 0.001) during the same time period. The mean annual number of emergency department visits for cases was 0.66 (95% CI 0.62–0.70) compared with 0.34 (95% CI 0.32–0.35) for controls (P < 0.0001).Conclusions:Individuals with constipation have higher medical care use. Outpatient costs and emergency department use were significantly greater for individuals with constipation from childhood to early adulthood.
Why Some Disabled Adults In Medicaid Face Large Out-Of-Pocket Expenses
Shah, Nilay D. , Burns, Marguerite E , Smith, Maureen P.

Mayo Clinic

Health Affairs | August 2, 2010 | Volume: 29 | Issue: 8 | Pages: 1517-1522

10.1377/hlthaff.2009.0147 | PMID 20679656 Get It

Staged protocol for initial management of the dislocated knee
Levy, Bruce A. , Krych, Aaron J. , Shah, Jay P. , Morgan, Joseph A. , Stuart, Michael J. , Krych, Aaron J

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | July 15, 2010 | Volume: 18 | Issue: 12 | Pages: 1630-1637

10.1007/s00167-010-1209-y | PMID 20635077 Get It

AbstractPurposeThe purpose of this study was (1) to describe a staged protocol for management of the dislocated knee and (2) to describe clinical and functional outcomes for patients who received initial spanning external fixation as part of this protocol.MethodNine knees in 9 patients, consisting of 6 males and 3 females, mean age 30.4 (range 19–44) years with diagnosis or presumption of knee dislocation were treated with a protocol of stabilization with external fixator. Mean follow‐up was 24 (range 13–42) months. Indications for spanning external fixation included significant vascular injury, gross instability on examination with failure to maintain joint reduction, open knee dislocation, inability to tolerate mobilization in a brace. The standard protocol involved vascular examination including ankle‐brachial index, ligamentous examination (under anesthesia when applicable), stabilization with temporary joint spanning external fixator, thromboprophylaxis, reconstructive knee surgery, and standard rehabilitation.ResultsMean range of motion (ROM) was 97.4° (range 80°–150°, SD 20.75, median 127.5). Median IKDC score was 80 (range 30–95), and mean Lysholm score was 76.7 (range 46–95). Heterotopic ossification (HO) was noted in 4 knees (44%).ConclusionThe treatment algorithm utilized in this series for management of the dislocated knee demonstrated satisfactory clinical and functional outcomes. This staged protocol provides a management option for those patients who may be best served with initial spanning joint external fixation. Larger prospective studies are needed to fully understand the merit of staged protocols in this setting.
Bioabsorbable Fixation of Unstable Osteochondritis Dissecans Lesions
Millington, Kendra L., Shah, Jay P. , Dahm, Diane L., Levy, Bruce A. , Stuart, Michael J.

Mayo Clinic

The American Journal of Sports Medicine | July 1, 2010 | Volume: 38 | Issue: 10 | Pages: 2065-2070

10.1177/0363546510371369 | PMID 20595548 Get It

Background Osteochondritis dissecans lesions of the knee in adult patients frequently require surgical intervention. However, the ideal method of osteochondral fragment fixation remains uncertain. Purpose This study was undertaken to determine the clinical, functional, and radiographic outcomes of bioabsorbable fixation for unstable osteochondritis dissecans lesions involving the femoral condyles of the knee in skeletally mature patients. Study Design Case series; Level of evidence, 4. Methods Skeletally mature patients with an unstable osteochondritis dissecans lesion of the femoral condyle (Ewing and Voto stages II-IV) treated with bioabsorbable internal fixation and minimum 1-year follow-up were included in this retrospective study cohort. Pre- and postoperative radiographs were reviewed and postoperative Lysholm and International Knee Documentation Committee (IKDC) scores were documented. Results A total of 21 knees in 21 patients satisfied the inclusion criteria, and 3 patients were lost to follow-up. The remaining 18 patients were evaluated at a mean of 59 months after surgery (range, 12-154 months). The 14 male and 4 female patients had a mean age of 19 years at the time of surgery (range, 14-39 years). Ewing and Voto classification included 8 stage II lesions, 9 stage III lesions, and 1 stage IV lesion. Fragment fixation methods included bioabsorbable nails (11), pins (3), darts (2), screws (1), and combined screws and darts (1). Mean postoperative Lysholm and IKDC scores were 85 and 82, respectively. Fragment union occurred in 12 knees (67%); the remaining 6 knees (33%) required removal of the loose fragment. Of the 11 patients treated with bioabsorbable nails, 2 (18%) required reoperation for nail back-out. Conclusion The authors recommend caution when using bioabsorbable fixation for osteochondritis dissecans lesions in skeletally mature patients because of the low rate of clinical healing and high complication rate. Failure with unthreaded fixation devices may be caused by inadequate compression and not necessarily be related to bioabsorbability.